USA
News & Media
Take a closer look at what we’re doing across Teva worldwide
Press releases
Aug 20 / 2019
Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States
Aug 7 / 2019
Teva Reports Second Quarter 2019 Financial Results
Revenues of $4.3 billion GAAP diluted loss per share of $0.63 Non-GAAP diluted EPS of $0.60 Spend base reduction of $2.7 billion since initiation of the restructuring plan in 2018; on-track to achieve $3.0 billion by the end of 2019 Full year 2019 revenues and EPS guidance reaffirmed
Jul 15 / 2019
Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder
The First Digital Maintenance Asthma Inhaler Therapy with Integrated Sensors Joins Teva’s Digital Rescue Inhaler Therapy to Provide Patients with Technology to Track Treatment Use
Top Stories
Read the latest Teva news
18 Jul 2019
Meet the Expert: Corey Sparks
Corey Sparks, VP of Finance and Controller of North America talks about what it's like to work at Teva.
11 Jul 2019
Social Impact at Teva—2018 Progress and More: A Conversation with Amalia Adler-Waxman
Social Impact at Teva—2018 Progress and More: A Conversation with Amalia Adler-Waxman, Vice President, Social Impact & Responsibility.
21 Jun 2019
Celebrating Pride Month At Teva
Teva’s Pride Employee Resource (ERG) group members reflect on the role the Stonewall Uprising played in their own lives and the important mission of the ERG for fostering a culture of inclusion.
